According to a recent report in genome Web, Vertex Pharmaceuticals is conducting phase III studies of its cystic fibrosis drug “Kalydeco” (Ivacaftor) based on the results from a phase II cross over study in 40 patients that had one non G551D CFTR gating mutation. Cystic Fibrosis is caused by mutations in the CFTR gene.
Vertex is conducting a study for children who are 2 to 5 years old and have gating mutations in the CFTR gene. The company is conducting two phase III studies known as “Traffic” and “Transport” for patients that are 12 years and older and have two copies of the F508del mutation in the CFTR gene. Children aged between 6 to 11 years old and who have two copies of F508del mutation are also being studied for Kalydeco/VX-809 drug therapy.
If you or someone you know would like to participate in a clinical study, please visit us at Reg4All and get connected to the clinical trial that is suitable for you.